Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$34.10+0.41%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · AMLX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Met or beat guidance 100% of the last 1 guided quarters · 34.8% avg surprise
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Prepare for New Drug Application submission by end of 2026 and potential commercial launch of avexitide in 2027 if approved.
Stated as a priority in 3 quarters including 2026-Q1 and 2026-Q2 and in the August 2026 press release. Management confirmed NDA submission planned by end of 2026 and potential commercial launch of avexitide in 2027 if approved. This aligns with the positive topline Phase 3 LUCIDITY trial results announced in 2026-Q3. The trajectory is delivering as the company advances regulatory and commercial readiness.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“We are continuing to advance NDA readiness and pre-commercial work to support potential submission and commercial launch of avexitide in 2027, if approved.”
“We have initiated regulatory and commercial readiness activities to help ensure we are positioned to move swiftly following LUCIDITY topline data.”
Complete enrollment and treatment in the pivotal Phase 3 LUCIDITY trial of avexitide in PBH and report topline data in 2026.
Stated as a priority in 3 quarters including 2026-Q1 and 2026-Q2 and confirmed with positive topline Phase 3 LUCIDITY results announced August 18, 2026. The trial met its primary and all secondary endpoints with a 55% reduction in hypoglycemic events. The trajectory is delivering with successful trial completion and data readout.
“Last participant completed final study visit in the 16-week double-blind period of the pivotal Phase 3 LUCIDITY trial; topline data anticipated late August or early September 2026.”
“Enrollment complete for pivotal Phase 3 LUCIDITY clinical trial; topline data readout anticipated in Q3 2026.”
Manage financial resources to sustain operations with cash runway expected into 2028 based on current operating plans.
Stated as a priority in 3 quarters including 2026-Q1 and 2026-Q2. Cash and equivalents declined from $279.8M at 2026-Q1 to $250.8M at 2026-Q2, consistent with operating cash outflows. Management continues to expect cash runway into 2028, aligning with current operating plans. The trajectory is delivering given the maintained runway despite ongoing losses.
“Based on current operating plans, Amylyx expects a cash runway into 2028.”
“Based on current operating plans, Amylyx expects a cash runway into 2028.”
“Cash runway expected into 2028, through potential approval and commercial launch of avexitide.”
Progress investigational GLP-1 receptor antagonist AMX0318 through IND-enabling studies aiming for IND submission in 2027.
Stated as a priority in 2 quarters, 2026-Q1 and 2026-Q2. Management reports IND-enabling studies underway for AMX0318 with a targeted IND filing in 2027. No financial or clinical milestone data yet available to assess progress. The trajectory is ongoing with preparatory work in progress.
“IND-enabling studies for AMX0318 underway with IND filing targeted for 2027.”
“IND-enabling studies for AMX0318 underway with IND filing targeted for 2027.”
Continue Phase 1 LUMINA trial of AMX0114, an antisense oligonucleotide for ALS, including enrollment and biomarker data presentation.
Stated as a priority in 2 quarters, 2026-Q1 and 2026-Q2. Management reports completion of enrollment for Cohorts 1 and 2 and ongoing enrollment for Cohort 3 in the Phase 1 LUMINA trial of AMX0114 for ALS. Biomarker data were presented in June 2026. The trajectory is delivering early clinical development milestones.
“Presented data from Phase 1 LUMINA trial of AMX0114 at ENCALS meeting in June 2026; Cohort 3 enrolling.”
“Completed enrollment of Cohort 2 of Phase 1 LUMINA trial of AMX0114; biomarker data expected at ENCALS meeting in June 2026.”
Over the trailing year it converted 0.33x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
8 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.